JP2004515463A5 - - Google Patents

Download PDF

Info

Publication number
JP2004515463A5
JP2004515463A5 JP2002512249A JP2002512249A JP2004515463A5 JP 2004515463 A5 JP2004515463 A5 JP 2004515463A5 JP 2002512249 A JP2002512249 A JP 2002512249A JP 2002512249 A JP2002512249 A JP 2002512249A JP 2004515463 A5 JP2004515463 A5 JP 2004515463A5
Authority
JP
Japan
Prior art keywords
concentration
metronidazole
aqueous solution
niacinamide
hpcd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002512249A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004515463A (ja
JP4130358B2 (ja
Filing date
Publication date
Priority claimed from US09/615,169 external-priority patent/US6468989B1/en
Application filed filed Critical
Publication of JP2004515463A publication Critical patent/JP2004515463A/ja
Publication of JP2004515463A5 publication Critical patent/JP2004515463A5/ja
Application granted granted Critical
Publication of JP4130358B2 publication Critical patent/JP4130358B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2002512249A 2000-07-13 2001-06-19 メトロニダゾール含有ゲル組成物 Expired - Lifetime JP4130358B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/615,169 US6468989B1 (en) 2000-07-13 2000-07-13 Gel compositions containing metronidazole
PCT/US2001/019644 WO2002006349A1 (en) 2000-07-13 2001-06-19 Gel compositions containing metronidazole

Publications (3)

Publication Number Publication Date
JP2004515463A JP2004515463A (ja) 2004-05-27
JP2004515463A5 true JP2004515463A5 (enExample) 2005-01-27
JP4130358B2 JP4130358B2 (ja) 2008-08-06

Family

ID=24464287

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002512249A Expired - Lifetime JP4130358B2 (ja) 2000-07-13 2001-06-19 メトロニダゾール含有ゲル組成物

Country Status (10)

Country Link
US (1) US6468989B1 (enExample)
EP (1) EP1303541B1 (enExample)
JP (1) JP4130358B2 (enExample)
AR (1) AR030245A1 (enExample)
AT (1) ATE506950T1 (enExample)
AU (1) AU2001269937A1 (enExample)
CA (1) CA2405072C (enExample)
DE (1) DE60144520D1 (enExample)
ES (1) ES2365322T3 (enExample)
WO (1) WO2002006349A1 (enExample)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6605751B1 (en) 1997-11-14 2003-08-12 Acrymed Silver-containing compositions, devices and methods for making
EP1244476B1 (en) 1999-12-30 2006-05-31 Acrymed Methods and compositions for improved delivery devices
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
US6881726B2 (en) * 2001-12-24 2005-04-19 Dow Pharmaceutical Sciences Aqueous compositions containing metronidazole
CN1678277B (zh) 2002-07-29 2010-05-05 艾克里麦德公司 治疗皮肤病的方法和组合物
US20060140984A1 (en) 2002-10-25 2006-06-29 Foamix Ltd. Cosmetic and pharmaceutical foam
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US8119109B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US8119150B2 (en) * 2002-10-25 2012-02-21 Foamix Ltd. Non-flammable insecticide composition and uses thereof
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US20080138296A1 (en) 2002-10-25 2008-06-12 Foamix Ltd. Foam prepared from nanoemulsions and uses
US7700076B2 (en) 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
US8486376B2 (en) 2002-10-25 2013-07-16 Foamix Ltd. Moisturizing foam containing lanolin
US7575739B2 (en) 2003-04-28 2009-08-18 Foamix Ltd. Foamable iodine composition
US8410102B2 (en) 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
US8486374B2 (en) 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
US20050090564A1 (en) * 2003-10-28 2005-04-28 Wegener Paul T. Compositions and treatments of bacterial vaginosis
ES2424644T3 (es) 2004-05-25 2013-10-07 Galderma Pharma S.A. Compuestos, formulaciones y métodos para tratar o prevenir los trastornos inflamatorios de la piel
FR2887149B1 (fr) * 2005-06-17 2007-08-03 Galderma Sa Procede de solubilisation du metronidazole
US8361553B2 (en) 2004-07-30 2013-01-29 Kimberly-Clark Worldwide, Inc. Methods and compositions for metal nanoparticle treated surfaces
EP2789235B1 (en) 2004-07-30 2015-12-23 Avent, Inc. Method of preparing silver nanoparticles
CN102783499A (zh) 2004-07-30 2012-11-21 金伯利-克拉克环球有限公司 抗微生物的装置和组合物
US9289378B2 (en) 2004-09-20 2016-03-22 Avent, Inc. Antimicrobial amorphous compositions
US20060093675A1 (en) * 2004-10-29 2006-05-04 Mathew Ebmeier Intravaginal treatment of vaginal infections with metronidazole compositions
BRPI0612448A2 (pt) 2005-05-09 2010-11-23 Foamix Ltd composição espumosa de sacarìdeo
FR2890559B1 (fr) * 2005-09-13 2011-06-24 Galderma Sa Mousses dermatologiques a base de metronidazole et emulsions pour la preparation
FR2890560B1 (fr) * 2005-09-13 2011-06-24 Galderma Sa Mousses dermatologiques a base de metronidazole et emulsions pour leur preparation
WO2007127236A2 (en) 2006-04-28 2007-11-08 Acrymed, Inc. Antimicrobial site dressings
US20080260655A1 (en) 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
WO2009069006A2 (en) 2007-11-30 2009-06-04 Foamix Ltd. Foam containing benzoyl peroxide
WO2009072007A2 (en) 2007-12-07 2009-06-11 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
WO2010041141A2 (en) 2008-10-07 2010-04-15 Foamix Ltd. Oil-based foamable carriers and formulations
CA2709199A1 (en) 2007-12-21 2009-07-02 Galderma Laboratories, Inc. Pre-surgical treatment
AU2009205314A1 (en) 2008-01-14 2009-07-23 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
US7893097B2 (en) 2008-02-02 2011-02-22 Dow Pharmaceutical Sciences, Inc. Methods and compositions for increasing solubility of azole drug compounds that are poorly soluble in water
US20100105750A1 (en) * 2008-10-23 2010-04-29 Nycomed Us Inc. Stable metronidazole gel formulations
US20120087872A1 (en) 2009-04-28 2012-04-12 Foamix Ltd. Foamable Vehicles and Pharmaceutical Compositions Comprising Aprotic Polar Solvents and Uses Thereof
WO2011013009A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
CA2769677A1 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
AU2010302350B2 (en) 2009-10-02 2015-06-18 Journey Medical Corporation Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
EP2329849B1 (en) 2009-11-18 2015-04-29 Galderma Research & Development Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder
US8394800B2 (en) * 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
CN103298472A (zh) 2010-03-26 2013-09-11 盖尔德马研究及发展公司 安全和有效治疗红斑的改进的方法和组合物
WO2011117378A2 (en) 2010-03-26 2011-09-29 Galderma Research & Development Improved methods and compositions for safe and effective treatment of telangiectasia
US12661407B2 (en) 2010-04-08 2026-06-23 Journey Medical Corporation Compositions, gels and foams with rheology modulators and uses thereof
RU2587041C2 (ru) 2010-06-30 2016-06-10 Галдерма Ресерч Энд Девелопмент Способ предотвращения или лечения опухоли кожи
AU2011273509A1 (en) 2010-06-30 2013-06-13 Galderma Research & Development Use of alpha-adrenergic receptor agonist for preventing or treating skin tumor
US8053427B1 (en) 2010-10-21 2011-11-08 Galderma R&D SNC Brimonidine gel composition
ES2498217T5 (es) 2010-10-21 2018-03-19 Galderma S.A. Composición en forma de gel basada en brimonidina
AU2012275292B2 (en) 2011-06-28 2015-11-12 Chemo Research, S.L. High dosage mucoadhesive metronidazole aqueous-based gel formulations their use to treat bacterial vaginosis
WO2013016072A1 (en) 2011-07-22 2013-01-31 Allergan, Inc. Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating skin diseases
WO2013057579A2 (en) 2011-10-19 2013-04-25 Galderma Pharma S.A. Method of reducing facial flushing associated with systemic use of phosphodiesterase type 5 inhibitors
PH12014500785A1 (en) 2011-10-19 2014-05-12 Galderma Sa Method for treating capillary hemangiomas
US9283217B2 (en) 2011-11-10 2016-03-15 Allergan, Inc. Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
UA109359C2 (xx) 2011-11-10 2015-08-10 Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном
WO2014113493A1 (en) 2013-01-16 2014-07-24 Emory University Cas9-nucleic acid complexes and uses related thereto
CN105209049B (zh) 2013-05-02 2019-05-14 医学科技研究公司 抗微生物组合物及其制造方法
KR102221499B1 (ko) 2013-09-26 2021-03-02 갈데르마 소시에떼아노님 위축성 피부 흉터를 치료하기 위한 프로스타글라딘 F2α 및 그 유사체
US10117911B2 (en) 2015-05-29 2018-11-06 Agenovir Corporation Compositions and methods to treat herpes simplex virus infections
AU2017241767B2 (en) 2016-03-28 2021-07-22 Allergan, Inc. Phenyl urea derivatives as N-formyl peptide receptor modulators
MX2020012139A (es) 2016-09-08 2021-01-29 Vyne Pharmaceuticals Inc Composiciones y metodos para tratar rosacea y acne.
CN110314133A (zh) * 2019-06-28 2019-10-11 石家庄四药有限公司 一种甲硝唑氯化钠注射液及其制备方法
EP4192431A1 (en) 2020-08-04 2023-06-14 Venthera, Inc. Formulations of phosphoinositide 3-kinase inhibitors
CA3255435A1 (en) 2022-05-20 2023-11-23 Dermbiont, Inc. Compositions and formulations allowing the use of a PK inhibitor for the prevention, treatment, and improvement of skin diseases, conditions, and disorders

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4032645A (en) 1975-06-19 1977-06-28 G. D. Searle & Co. Injectable metronidazole composition
DE3346123A1 (de) 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
US4596795A (en) 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4837378A (en) * 1986-01-15 1989-06-06 Curatek Pharmaceuticals, Inc. Topical metronidazole formulations and therapeutic uses thereof
DE3773383D1 (de) * 1987-03-20 1991-10-31 Curatek Pharmaceuticals Neue topische metronidazol-formulierungen.
US5536743A (en) 1988-01-15 1996-07-16 Curatek Pharmaceuticals Limited Partnership Intravaginal treatment of vaginal infections with buffered metronidazole compositions
EP0335545B2 (en) 1988-03-29 1998-09-23 University Of Florida Pharmaceutical formulations for parenteral use
US5997856A (en) 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
TW200402B (enExample) 1990-08-13 1993-02-21 Senju Pharma Co
DE69232535T4 (de) * 1991-06-24 2003-09-11 Hcell Technology, Inc. In langzeitkultur gehaltene hormon-absondernde pankreatische zellen
US5747341A (en) * 1991-06-24 1998-05-05 Pacific Biomedical Research, Inc. Culture media having low osmolarity for establishing and maintaining hormone-secreting cells in long-term culture
US5602112A (en) * 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
US5472954A (en) 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
US5324718A (en) * 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
US5298410A (en) * 1993-02-25 1994-03-29 Sterling Winthrop Inc. Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life
JPH07157440A (ja) * 1993-10-15 1995-06-20 Takeda Chem Ind Ltd 医薬用組成物
FR2722098B1 (fr) 1994-07-06 1996-08-23 Cird Galderma Nouveaux medicaments a base de metro-nidazole ou d'un melange synergetique de metronidazole et de clindamycine
KR20010023256A (ko) * 1997-08-27 2001-03-26 헥살 아게 용해도와 생체 이용성이 개선된 신규의 멜록시캄 의약조성물
US5989523A (en) * 1998-03-20 1999-11-23 Fitzjarrell; Edwin A. Topical spray for treating acne containing niacinamide and NaPCA
WO2000015224A1 (en) * 1998-09-17 2000-03-23 Eli Lilly And Company Protein formulations
US6183766B1 (en) * 1999-02-12 2001-02-06 The Procter & Gamble Company Skin sanitizing compositions
EP1383445A4 (en) * 2001-03-20 2005-04-13 Cydex Inc FORMULATIONS WITH PROPOFOL AND A SULFOALKYL ETHER CYCLODEXTRIN
US6881726B2 (en) * 2001-12-24 2005-04-19 Dow Pharmaceutical Sciences Aqueous compositions containing metronidazole

Similar Documents

Publication Publication Date Title
JP2005532990A5 (enExample)
RU2004122696A (ru) Водные композиции, содержащие метронидазол
BR0309890A (pt) Composição farmacêutica contendo plasma sanguìneo, ou soro sanguìneo utilizada no tratamento de lesões, bem como seu método e processo de aplicação
NO20050009L (no) Blandinger og fremgangsmater for behandling av en undergrunnsformasjon
DE60126947D1 (de) Behandlung der glykogenspeicherkrankheit typ ii
DE60323936D1 (de) Bioabbaubare polyketale, verfahren zu ihrer herstellung sowie ihre verwendung
CA2342856A1 (en) Stabilized two-part disinfecting system and compositions and methods related thereto
DE69906269D1 (de) Wässriges verfahren zur herstellung fester paroxetin-dispersionen
CA2527120A1 (en) Stable aqueous solution of natamycin fungicide
CA2407684A1 (en) Hematology blood control and method for preparation of same
WO2005115416A3 (en) Method of treating with chlorine dioxide
DE60218227D1 (de) Topisches dapson zur behandlung von akne
DE50014164D1 (de) Verfahren zur herstellung einer wasserunlöslichen amorphen retardmatrix
JP2005519863A5 (enExample)
US20080089914A1 (en) Low pH Pharmacologically active products and methods for the production thereof
JP2009536649A5 (enExample)
DE60217899D1 (de) Einschlusskomplex von taxol mit 2-hydroxypropyl-beta-cyclodextrin
SE0100949L (sv) Jordbruks- och trädgårdskomposition
ATE321045T1 (de) Methoden und zusammensetzungen zur behandlung von schmerzen
DE60013326D1 (de) Verbindungen und verfahren zur behandlung von schmerz
RU99127483A (ru) Способ бальзамирования анатомических препаратов силоксановыми композициями
DE60230298D1 (de) Herstellung von mikropartikeln
AR034554A1 (es) Un metodo para mejorar la distribucion de un ingrediente activo en un licor de curtido, una tableta o bloque para ser usado en dicho metodo, y el uso de dicha tableta o bloque en el curtido de cuero
CN1216537C (zh) 原子碘水溶液及其配制方法
WO2004032854A3 (en) Pharmaceutical compositions for treatment of parkinson's disease